|Articles|December 8, 2008

LEO Pharma establishes company in China

Shanghai, China - LEO Pharma is establishing a strategic company in China to market drugs for the treatment of psoriasis and other skin diseases, MarketWatch reports.

Shanghai, China

- LEO Pharma is establishing a strategic company in China to market drugs for the treatment of psoriasis and other skin diseases, MarketWatch reports.

LEO Pharma China, the new company, will market Daivobet, LEO Pharma's psoriasis brand, which was recently approved by the Chinese authorities in order to market the drug in China.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!

Related Content

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD
In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Register now!
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
Multimedia

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

View more
Burst CME: Targeted Therapy for Optimal Psoriasis Management
Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

View more
Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)
Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

View more
Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities
Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

View more
Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis
Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

View more
Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management
Video

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

View more